Halaven 0.44 mg (2ml)

Halaven 0.44 mg is a anti-cancer drug manufactured under licence by NerPharma, marketed by Eisai Pharmaceuticals. Its generic name is Eribulin Mesylate. It is a drug approved by the US FDA for treatment of patients with metastatic breast cancer who have previously received two chemotherapeutic regimens for the treatment of metastatic disease.Previous therapy should have included an anthracycline and a taxane for either early or advanced breast cancer. It is in powder form in vial along with a solvent. Dosage is 0.88 mg/2ml. 

Manufacturer: Eisai Pharmaceuticals (Contract Manufacturer: NerPharma SRL, Italy)

Side Effects:

1. The most common side effects reported in ≥25% of patients receiving Halaven (eribulin mesylate) were low white blood cells; low red blood cells; weakness/tiredness; hair loss; numbness, tingling, or burning in the hands and feet; nausea; and constipation
2. The most common serious side effects reported in patients receiving Halaven (Eribulin Mesylate) were neutropenia with or without a fever.